Sun Pharmaceutical Industries has entered into agreement to acquire stake ~16.7% shares on fully diluted basis, in Lyndra Therapeutics, Inc., a company based in Massachusetts, engaged in the business of developing novel delivery technology for long-acting oral (LAO) therapies.

The cost of acquisition is USD 30 million.